References
- Pharmacy Benefit Management Institute. 2011–2012 Prescription Drug Benefit Cost and Plan Design Report. [online]. Plano, TX: Pharmacy Benefit Management Institute, LP, 2011. http://www.benefitdesignreport.com/. Accessed August 6, 2012
- Yokoyama K, Yang W, Preblick R, et al. Effects of a step-therapy program for angiotensin receptor blockers on antihypertensive medication utilization patterns and cost of drug therapy. J Manag Care Pharm 2007;13:235–44
- Dunn JD, Cannon E, Mitchell MP, et al. Utilization and drug cost outcomes of a step-therapy edit for generic antidepressants in an HMO in an integrated health system. J Manag Care Pharm 2006;12:294–302
- Lu CY, Law MR, Soumerai SB, et al. Impact of prior authorization on the use and costs of lipid-lowering medications among Michigan and Indiana dual enrollees in Medicaid and Medicare: results of a longitudinal, population-based study. Clin Ther 2011;33:135–44
- Law MR, Lu CY, Soumerai SB, et al. Impact of two Medicaid prior-authorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: results of a longitudinal, population-based study. Clin Ther 2010;32:729–41
- Motheral BR, Henderson R, Cox ER. Plan-sponsor savings and member experience with point-of-service prescription step therapy. Am J Manag Care 2004;10:457–564
- Margolis JM, Johnston SS, Chu BC, et al. Effects of a Medicaid prior authorization policy for pregabalin. Am J Manag Care 2009;15:e95–102
- Margolis JM, Cao Z, Onukwugha E, et al. Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans. Am J Manag Care 2010;16:447–56
- Mark TL, Gibson TB, McGuigan KA. The effects of antihypertensive step-therapy protocols on pharmaceutical and medical utilization and expenditures. Am J Manag Care 2009;15:123–31
- Mark TL, Gibson TM, McGuigan K, et al. The effects of antidepressant step therapy protocols on pharmaceutical and medical utilization and expenditures. Am J Psychiatry 2010;167:1202–9
- Lyrica® [pregabalin] capsules prescribing information. New York, NY: Pfizer, Inc., 2012
- Neurontin® [gabapentin] prescribing information. New York, NY: Pfizer, Inc., 2011
- Arnold LM, Goldenberg D, Stanford SB, et al. Gabapentin in the treatment of fibromyalgia. A randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 2007;56:1336–44
- Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998;280:1831–6
- Fishman PA, Goodman MJ, Hornbrook MC, et al. Risk adjustment using automated ambulatory pharmacy data: the RxRisk model. Med Care 2003;41:84–99
- Sloan KL, Sales AE, Liu CF, et al. Construction and characteristics of the RxRisk-V: a VA-adapted pharmacy-based case-mix instrument. Med Care 2003;41:761–74
- Sales AE, Liu CF, Sloan KL, et al. Predicting costs of care using a pharmacy-based measure risk adjustment in a veteran population. Med Care 2003;41:753–60
- Kleinbaum DG, Klein M. Logistic Regression. A Self-Learning Text. 3rd ed. New York, NY: Springer-Verlag, 2010
- Littell RC, Milliken GA, Stroup WW, et al. SAS® for Mixed Models. 2nd ed. Cary, NC: SAS Institute Inc., 2006
- Vonesh EF. Generalized linear and nonlinear models for correlated data: theory and applications using SAS. Cary, NC: SAS Institute Inc., 2012
- Motheral BR. Pharmaceutical step-therapy interventions: a critical review of the literature. J Manag Care Pharm 2011;17:143–55
- Mackinnon NJ, Kumar R. Prior authorization programs: a critical review of the literature. J Manag Care Pharm 2001;7:297–302
- Shoemaker SJ, Pozniak A, Subramanian R, et al. Effect of 6 managed care pharmacy tools: a review of the literature. J Manag Care Pharm 2010;16:S3–20
- Duan N. Smearing estimate: a nonparametric retransformation method. J Am Stat Assoc 1983;78:605–10